Nazara Technologies Ltd has extended the timeline for infusing funds into its wholly owned subsidiary, Nazara Technologies UK Limited, to August 14, 2026. The company plans to invest a total amount not exceeding USD 100.3 million through equity subscription and loans.

The proposed capital infusion is divided into two parts. The company will subscribe to equity shares for an amount not exceeding USD 40.1 million. Additionally, it will provide a loan not exceeding USD 60.2 million to the subsidiary.

This update relates to a disclosure originally made on March 18, 2026, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The extension applies to the indicative timeline for completing this fund infusion.

Breakdown of Fund Infusion

The funds will be disbursed in one or more tranches, subject to compliance with applicable laws. Nazara Technologies UK Limited remains a wholly owned subsidiary of the company.

Nazara Technologies has scheduled a series of investor and analyst meetings for June 17 and June 18, 2026, in Mumbai. The company's representatives will engage with Ventura Securities and Ambit Capital to discuss business performance and strategy based on publicly available information.

The meetings are being conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted by Arun Bhandari, Company Secretary and Compliance Officer.

The schedule includes two virtual one-on-one meetings. The details of the interactions are outlined below:

Discussions during these sessions will rely solely on publicly available information. The company noted that changes to the schedule may occur due to exigencies on the part of the participants or the company.